Amgen Q1 beats: revenue $8.1B (+9%), non-GAAP EPS $4.90 (+24%), FCF $1.0B

AMGEN INC

2025-Q1 EPS reported $3.20 revenue$8,149,000,000

GAAP EPS $3.20 vs -$0.21; includes $800M Otezla intangible impairment.
Non-GAAP EPS $4.90 (+24% YoY) on revenue $8.1B (+9%).
Product sales up 11% with 14% volume growth; 14 products had double-digit growth.
Free cash flow $1.0B vs $0.5B prior year, driven by business performance.
IMDELLTRA sales $81M; Phase 3 confirmatory trial improved overall survival vs chemo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.